New combo therapy shows promise for tough bladder cancer
NCT ID NCT03747419
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether adding the immunotherapy drug avelumab to standard radiation could help treat muscle-invasive bladder cancer in patients who cannot receive the usual chemotherapy. Fourteen participants received the combination therapy. The goal was to see if the cancer disappeared completely after treatment. The study was stopped early, so results are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02215, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02115, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Bag-Like device pull bladder tumors out whole?
- Can Pre-Surgery chemotherapy outsmart aggressive bladder cancer?
- Bladder cancer: a new combo aims to avoid radical surgery
- Can a special PET scan see bladder cancer more clearly?
- Could a simple urine test spare bladder cancer patients from chemotherapy?
- Can a new drug rally the immune system against Hard-to-Treat cancers?